Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review
토실리주맙으로 치료한 코로나19 환자의 임상 결과: 개별 환자 데이터 체계적 검토
Article
[키워드] acute respiratory distress
acute respiratory syndrome
added
analyzed
anti-IL-6
anti-interleukin-6 receptor antibody
average
baseline
baseline characteristics
C-reactive protein (CRP
Case report
cause
changes in
Characteristics
clinical
Clinical outcome
clinical outcomes
Comorbidity
coronavirus
coronavirus disease
COVID-19
COVID-19 patient
CRP level
current
cytokine release storm
Cytokine storm
decrease
demographics
elevated
Endpoint
Evidence
Fisher
hospital
hyperinflammatory state
hypertension
IL-6
IL-6 level
IL-6 pathway
in-hospital complications
in-hospital mortality
inclusion criteria
individual level
individual patient data
inflammatory markers
inhibition
interleukin-6
interquartile range
knowledge
Laboratory
male
median
nonsurvivor
not significantly different
observational study
occurred
outcome
over
pathway
Patient
patient data
patients
performed
primary endpoint
Primary outcome
randomized control trial
recent
receptor
reported
SARS-CoV-2
secondary
severe COVID-19
significantly
significantly higher
Standard deviation
surviving patients
survivor
syndrome
systematic review
the primary endpoint
therapy
Tocilizumab
treated
Treatment
worsened disease
[DOI] 10.1002/jmv.26038 PMC 바로가기 [Article Type] Article
[DOI] 10.1002/jmv.26038 PMC 바로가기 [Article Type] Article